Biotie announces agreement with FDA on a SPA for tozadenant phase 3 study
Biotie has reached agreement with the FDA on a Special Protocol Assessment for a Phase 3 study of tozadenant in Parkinson's disease. The Phase 3 study (TOZ-PD) will evaluate efficacy and safety of tozadenant compared to placebo in PD patients taking levodopa and experiencing end-of-dose wearing off. May 25, 2015